ArticleCell regeneration (London, England)2026
A novel strategy to generate human iPSCs with enhanced mesodermal and endodermal differentiation capacity.
Article in Cell regeneration (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Induced pluripotent stem cells (iPSCs) have unlimited proliferative capacity and multi-lineage differentiation potential. Autologous iPSC-derived cells reduce the risk of immune rejection, making them promising resources for regenerative medicine. However, iPSCs derived using conventional methods often show heterogeneity and defects in differentiation potential in a subset of cells. To overcome these limitations, we developed a novel reprogramming strategy, termed the "4CL-primed" strategy, that incorporates a transient early-pluripotency (4CL) treatment during reprogramming. The 4CL-primed iPSCs retained the core characteristics of conventional iPSCs, including normal morphology, pluripotency marker expression, and karyotypic stability, while exhibiting enhanced mesodermal and endodermal differentiation capacity. Furthermore, the cells showed superior performance in directed pancreatic lineage differentiation, generating a higher proportion of pancreatic endocrine β-like cells. Collectively, the 4CL-primed strategy offers a more practical approach for mesodermal and endodermal differentiation research, particularly pancreatic lineage differentiation, thereby providing a more efficient source of pancreatic lineage cells for regenerative medicine and cell-based therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.